The Children’s Eye Foundation of AAPOS unveiled the world’s first interactive children’s book to help screen for color vision deficiency (CVD), commonly known as color blindness. The foundation posted a free digital version of THE CURIOUS EYE at thecuriouseye.org and published a first-run, hardcover book for its member pediatric ophthalmologists.
Novartis’ Beovu matched Regeneron’s Eylea in vision clarity scores for a blindness-causing eye disease, the Swiss drugmaker said, after early safety stumbles for the medicine in another condition caused disappointing early sales.
Johnson & Johnson Vision announced the launch of Prioritize Your Eyes, a worldwide effort to raise awareness about the connection of eye health to overall health.
Late-stage data released from Regeneron highlights the importance of proactively providing Eylea to patients who have been diagnosed with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) in order to prevent issues that could lead to the loss of vision.
The U.S. FDA gave Alexion Pharmaceuticals a thumbs-up for Soliris (eculizumab) to treat neuromyelitis optica spectrum disorder in adults that express a specific biomarker.
Sangamo Therapeutics Inc.’s shares sank 27 percent after the company’s gene-editing drug failed to show promise in an early-stage trial testing for patients with ultra-rare disorders.
Pixium Vision announced that the bioelectronics company’s subretinal PRIMA system met the endpoints of the feasibility study, at interim 6 months follow-up after implantation and rehabilitation for patients with advanced dry age-related macular degeneration (AMD).
Researchers at Johns Hopkins University, the University of California, San Diego (UCSD), and the National Institute of Mental Health grew retinas in Petri dishes and discovered fundamental factors involved in the development of vision and color vision.
An interim analysis of an early-stage trial showed that ProQR Therapeutics NV’s experimental treatment for a rare form of childhood blindness improved vision.
Clearside Biomedical Inc. said the drug developer’s treatment helped improve vision in patients with fluid buildup in the eye in a late-stage study.